<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04025177</url>
  </required_header>
  <id_info>
    <org_study_id>B2018:095</org_study_id>
    <nct_id>NCT04025177</nct_id>
  </id_info>
  <brief_title>Indomethacin PK-PD in Extremely Preterm Neonates</brief_title>
  <acronym>INDO</acronym>
  <official_title>Pharmacokinetics and Pharmacodynamics of Indomethacin Used for PDA Treatment in Extremely Preterm Neonates &lt;27 Weeks Gestational Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Manitoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Boniface Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Health Sciences Centre, Winnipeg, Manitoba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University at Buffalo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Manitoba</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II open-label study evaluating the pharmacokinetics and pharmacodynamics of&#xD;
      targeted early use of indomethacin for PDA treatment in preterm neonates &lt;27 weeks'&#xD;
      gestational age.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neonates will be enrolled following an echocardiogram performed within 12 hours after birth&#xD;
      that confirms an open PDA (with no other contraindications for indomethacin treatment). After&#xD;
      enrollment, neonates will receive intravenous indomethacin at a dose of 0.1mg/kg every 24&#xD;
      hours for 3 days. Indomethacin levels will be measured at regular intervals. Urine output and&#xD;
      serum electrolytes will be monitored prior to each dose of indomethacin. An echocardiogram&#xD;
      will be repeated after completion of indomethacin treatment (between 72-120 hours of age) to&#xD;
      reassess the status of PDA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Halted due to feasibility issues&#xD;
  </why_stopped>
  <start_date type="Anticipated">January 2020</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve from serial Indomethacin levels</measure>
    <time_frame>At 48 hour following the last dose</time_frame>
    <description>Blood samples will be drawn from patients to determine the serum indomethacin levels to determine the area under the curve</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Patent Ductus Arteriosus Closure</measure>
    <time_frame>Within 48 hrs after the last dose</time_frame>
    <description>Confirmed by echocardiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Intraventricular hemorrhage</measure>
    <time_frame>Within the first 7 days of life.</time_frame>
    <description>Confirmed by cranial ultrasound performed and graded using Papile's classification system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation of each patient</measure>
    <time_frame>trough hospital discharge, an average of up to 36 weeks gestational age</time_frame>
    <description>Number of days the infant was intubated and ventilated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events</measure>
    <time_frame>trough hospital discharge, an average of up to 36 weeks gestational age</time_frame>
    <description>development of any type A adverse reactions in the infants receiving indomethacin therapy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Patent Ductus Arteriosus After Premature Birth</condition>
  <arm_group>
    <arm_group_label>Neonates with an open PDA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neonates born between 23 (0/7) and 26 (6/7) weeks gestational age with an open PDA, according to clinical protocol criteria, and no contraindication to the use of indomethacin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indomethacin Injection</intervention_name>
    <description>The dose of indomethacin will be 0.1 mg/kg/dose, based on birth weight, intravenously every 24 hours for a total of 3 doses. Doses 2 and 3 may be administered between 23.5 and 24.5 hours after the previous dose. Doses will be rounded to two significant figures.</description>
    <arm_group_label>Neonates with an open PDA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female infant born between 23 (0/7) and 26 (6/7) week GA&#xD;
&#xD;
          -  Infant diagnosed with PDA according to clinical protocol criteria&#xD;
&#xD;
          -  Able to adhere to indomethacin administration protocol&#xD;
&#xD;
          -  The patient is born in the study center.&#xD;
&#xD;
          -  Subject's parent(s)/legal guardian(s) has provided signed and dated informed consent&#xD;
             and authorization to use protected health information, as required by national and&#xD;
             local regulations.&#xD;
&#xD;
          -  In the investigator's opinion, the subject's parent(s)/legal guardian(s) understand(s)&#xD;
             and can comply with protocol requirements, instructions, and protocol-stated&#xD;
             restrictions, and is likely to complete the study as planned.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  known major congenital malformations (renal, cardiac, gastrointestinal and central&#xD;
             nervous system)&#xD;
&#xD;
          -  genetic syndromes-inborn errors of metabolism&#xD;
&#xD;
          -  severe renal compromise&#xD;
&#xD;
          -  intrauterine growth retardation with birth weight &lt;3rd centile&#xD;
&#xD;
          -  thrombocytopenia &lt;50,000/mm3&#xD;
&#xD;
          -  moderate to severe pulmonary hypertension&#xD;
&#xD;
          -  clinical sepsis -meningitis- hepatitis&#xD;
&#xD;
          -  anticipated drug-drug-interactions (specifically CYP2C9, CYP2C19 and UGT 1-1)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>23 Weeks</minimum_age>
    <maximum_age>26 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deepak Louis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Manitoba</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Boniface General Hospital Research Centre</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2H 2A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Sciences Centre</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1R9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 27, 2019</study_first_submitted>
  <study_first_submitted_qc>July 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2019</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Indomethacin</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Preterm birth</keyword>
  <keyword>Pharmacodynamics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Ductus Arteriosus, Patent</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Indomethacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

